A long-running study may exhaust one lot before the work is complete. Planning the transition while material and records from the earlier lot remain available gives the team a better opportunity to assess continuity than discovering the change only after the results shift.
Identify what continuity means for this study
Start with the measurement or biological comparison that must remain interpretable. A transition plan should address that property, not attempt to prove that two lots are identical in every possible respect.
Review the molecular description, supplied form, amount basis and applicable analytical documents for both lots. A difference in those fields may require a different assessment from a routine replenishment with matching specifications.
Plan while a comparison with the previous lot is still possible where the study requires it. Do not assume that indefinitely retained material remains suitable; its documented condition and history also matter.
The transition is a research-design decision. It is distinct from recording multiple lots in inventory or receiving a supplier’s notice that a process has changed.
Make the comparison capable of answering the question
Algeciras-Schimnich and colleagues examined lot changes in a clinical IGF-1 assay at two institutions. Their routine lot comparisons did not identify significant differences, while retrospective analysis of reported results showed shifts; the authors found the comparison protocols underpowered. This concerns that diagnostic assay, not a universal peptide-lot rule.Algeciras-Schimnich et al. — Failure of current laboratory protocols to detect lot-to-lot reagent differences (2013) (opens in a new tab)
The general planning lesson is to ask whether the proposed comparison can detect a difference large enough to matter to the study. A small convenient comparison may provide limited evidence even when it produces no statistically significant result.
| Decision element | Question before comparison |
|---|---|
| Property | Which response or material characteristic must remain comparable? |
| Acceptance basis | What difference would matter, and why? |
| Design | Can the comparison separate lot from day, operator or instrument effects? |
| Evidence strength | Is precision and sample coverage adequate for the intended conclusion? |
The original study’s sample-size conclusions should not be copied into an unrelated assay. The required design depends on variability, the relevant difference and the laboratory’s own measurement context.
Avoid making lot identical to time or treatment
In a hypothetical experiment, all baseline samples use lot A and all later samples use lot B. A shift between periods could reflect the study effect, the lot transition or another coincident change; the data cannot automatically distinguish them.
A planned comparison can reduce this ambiguity by evaluating the lots under appropriately comparable conditions. The specific design belongs to the study team and should be documented before results are interpreted.
Retain the lot identifier in the analysis dataset rather than only in a purchasing record. This allows the transition to be examined without reconstructing it from memory.
Record the transition and subsequent monitoring
State the evidence reviewed, decision made and point at which the new lot entered the study. If a limitation remains, carry it into the interpretation rather than hiding the lot boundary when combining results.
Where the project monitors performance over time, retain that record after the transition. Later drift may prompt investigation without proving that the new lot caused it.
A good transition plan preserves a defensible comparison and a visible history. It supports continuity while acknowledging that matching labels and an inconclusive test cannot establish universal equivalence.
Sources and further detail
- Algeciras-Schimnich et al. — Failure of current laboratory protocols to detect lot-to-lot reagent differences (2013) (opens in a new tab)
Original study abstract inspected for its clinical IGF-1 assay, retrospective findings and power limitation. No diagnostic conclusions or assay-specific sample-size threshold are transferred to research peptides.
Sources checked 20 September 2026. Inventory examples are hypothetical research records, not Novum stock, fulfilment procedures or validated laboratory systems. This article has not undergone independent scientific peer review.